Eli Lilly is expanding its India specialty pipeline by making Alzheimer’s disease a central bet, alongside obesity and metabolic therapies. The company launched Lormalzi (donanemab), a once-monthly intravenous treatment aimed at amyloid plaques driving early symptomatic Alzheimer’s, unlike older drugs that mainly ease symptoms. Lormalzi is priced at Rs 91,688 per 350 mg vial, delivered every four weeks for up to 18 months, and will roll out through hospitals and pharmacies with an alternative access program. Lilly also cites diagnosis delays, expecting blood-based biomarkers to help.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
